IL138021A0 - High affinity humanized anti-tag-72 monoclonal antibodies - Google Patents

High affinity humanized anti-tag-72 monoclonal antibodies

Info

Publication number
IL138021A0
IL138021A0 IL13802198A IL13802198A IL138021A0 IL 138021 A0 IL138021 A0 IL 138021A0 IL 13802198 A IL13802198 A IL 13802198A IL 13802198 A IL13802198 A IL 13802198A IL 138021 A0 IL138021 A0 IL 138021A0
Authority
IL
Israel
Prior art keywords
tag
monoclonal antibodies
high affinity
humanized anti
affinity humanized
Prior art date
Application number
IL13802198A
Other languages
English (en)
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Publication of IL138021A0 publication Critical patent/IL138021A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5756Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumour-associated glycolinkage [TAG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL13802198A 1998-02-25 1998-02-25 High affinity humanized anti-tag-72 monoclonal antibodies IL138021A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/003679 WO1999043816A1 (en) 1998-02-25 1998-02-25 High affinity humanized anti-tag-72 monoclonal antibodies

Publications (1)

Publication Number Publication Date
IL138021A0 true IL138021A0 (en) 2001-10-31

Family

ID=22266462

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13802198A IL138021A0 (en) 1998-02-25 1998-02-25 High affinity humanized anti-tag-72 monoclonal antibodies

Country Status (9)

Country Link
EP (1) EP1056860B1 (de)
JP (1) JP4080692B2 (de)
AT (1) ATE288960T1 (de)
AU (1) AU758358B2 (de)
CA (1) CA2321932A1 (de)
DE (1) DE69829001T2 (de)
IL (1) IL138021A0 (de)
NO (1) NO20004250L (de)
WO (1) WO1999043816A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
CA2348698C (en) * 1998-10-31 2012-01-03 Syed V. S. Kashmiri Variants of humanized anti-carcinoma monoclonal antibody cc49
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
EP1532162B1 (de) 2002-06-28 2013-08-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Humanisierter anti-tag-72 cc49 zur diagnose und therapie humaner tumore
WO2005021594A2 (en) 2003-08-29 2005-03-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use
KR100620554B1 (ko) * 2004-06-05 2006-09-06 한국생명공학연구원 Tag-72에 대한 인간화 항체
US8101728B2 (en) 2005-04-28 2012-01-24 Danisco Us Inc. TAB molecules
CA2609142C (en) 2005-05-27 2016-02-09 Fondazione Centro San Raffaele Del Monte Tabor Therapeutic gene vectors comprising mirna target sequences

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE64966B1 (en) * 1988-10-19 1995-09-20 Dow Chemical Co A novel family of high affinity modified antibodies for cancer treatment

Also Published As

Publication number Publication date
NO20004250L (no) 2000-10-24
EP1056860B1 (de) 2005-02-09
WO1999043816A1 (en) 1999-09-02
AU758358B2 (en) 2003-03-20
NO20004250D0 (no) 2000-08-24
JP2002504371A (ja) 2002-02-12
DE69829001T2 (de) 2006-03-23
EP1056860A1 (de) 2000-12-06
JP4080692B2 (ja) 2008-04-23
ATE288960T1 (de) 2005-02-15
CA2321932A1 (en) 1999-09-02
AU6439398A (en) 1999-09-15
DE69829001D1 (de) 2005-03-17

Similar Documents

Publication Publication Date Title
BR0311792A (pt) Anticorpo de receptor anti-igf-i
SG170080A1 (en) Human monoclonal antibodies to o8e
WO2005080431A3 (en) Monoclonal antibodies that specifically bind to folate receptor alpha
WO1998035693A3 (en) Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease
EA200800094A1 (ru) Антитела cd19 и их использование
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
EP2196474A3 (de) Therapeutische Zielmolekulen in Krebs
IN2009KN02404A (de)
HUP9901562A2 (hu) Anti-CEA monoklonális antitestek, az ezeket tartalmazó konjugátumok és ezek felhasználása antitest irányított enzimes előgyógyszer terápiában
WO2004058146A3 (en) Novel compositions and methods in cancer
IL139700A0 (en) Immunotherapeutic composition and method for the treatment of prostate cancer
IL148113A0 (en) Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
SG146644A1 (en) Kid3 and kid3 antibodies that bind thereto
WO2004060304A3 (en) Novel compositions and methods in cancer
WO2003064593A3 (en) Antigen panels and methods of using the same
WO2002064839A3 (en) Methods for the diagnosis and treatment of tumors employing the hepsin gene
IL138021A0 (en) High affinity humanized anti-tag-72 monoclonal antibodies
NO20004251L (no) Humaniserte anti-CEA monoklonale antistoffer med høy affinitet
WO2003080808A3 (en) Novel compositions and methods in cancer
EA200601405A1 (ru) Гуманизированное антитело
EA200600995A1 (ru) Молекулы, ингибирующие ангиогенез, и их применение в лечении и диагностике рака
WO2002057786A3 (en) Compositions and methods for the use of fibronectin fragments in the diagnosis of cancer
AU2001233917A1 (en) Bcmp-7 as marker for diagnosis of breast cancer
WO2004101762A3 (en) Detection and treatment of cancers of the colon